InvestorsHub Logo
Followers 0
Posts 56
Boards Moderated 0
Alias Born 05/09/2016

Re: Jabramowitz post# 141

Thursday, 12/12/2019 12:10:39 PM

Thursday, December 12, 2019 12:10:39 PM

Post# of 188
Phase 2 Bertilimumab Trial
On May 15, 2018 our licensee announced positive Phase 2 data for the treatment of moderate-to-extensive bullous pemphigoid. iCo Therapeutics is eligible to receive up to $32M in potential future milestone payments. For more information please refer to:
www.immunepharma.com/immune-pharmaceuticals-presents-updated-positive-results-from-phase-2-trial-of-bertilimumab-in-bullous-pemphigoid/

ALEXION PHARMACEUTICALS TOOK OVER THIS LICENSE FROM IMNP BANKRUPTCY